The safety and imaging performance of 68Ga-PSMA-R2 for detecting potential PSMA-positive lesions in patients with BCR or mPC supports the use of 68Ga-PSMA-R2 as an imaging agent for patients with PC. Here, BCR is linked to pachyonychia congenita.